These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12164561)

  • 1. Combination chemotherapy should be standard of care for lung cancer.
    Oncology (Williston Park); 2002 Jul; 16(7):962, 986. PubMed ID: 12164561
    [No Abstract]   [Full Text] [Related]  

  • 2. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
    Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
    Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
    Belani CP
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?
    Besse B; Le Chevalier T
    J Clin Oncol; 2008 Nov; 26(31):5014-7. PubMed ID: 18809602
    [No Abstract]   [Full Text] [Related]  

  • 7. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
    Nyman J; Friesland S; Hallqvist A; Seke M; Bergström S; Thaning L; Lödén B; Sederholm C; Wagenius G
    Lung Cancer; 2009 Jul; 65(1):62-7. PubMed ID: 19081652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel poliglumex/carboplatin is similar to paclitaxel/carboplatin as first-line treatment in elderly patients with advanced non-small-cell lung cancer and a poor performance status.
    Reddy GK
    Clin Lung Cancer; 2005 Jul; 7(1):20-2. PubMed ID: 16098240
    [No Abstract]   [Full Text] [Related]  

  • 9. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
    J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
    Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small-cell lung cancer: results from the SPIRIT I and II trials.
    Tyagi P
    Clin Lung Cancer; 2005 Jul; 7(1):17-9. PubMed ID: 16098239
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms.
    Socinski MA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4210s-4214s. PubMed ID: 15217960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects on the immune system and toxicity of carboplatin/paclitaxel combination chemotherapy in patients with stage III-IV ovarian and non small cell lung cancer and its role in survival and toxicity.
    Hatziveis K; Tourlakis D; Hountis P; Kyriazanos I; Sougleri M; Ginopoulos P; Camoutsis C
    J BUON; 2012; 17(1):143-8. PubMed ID: 22517709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.
    Rowinsky EK; Flood WA; Sartorius SE; Bowling MK; Wagner J; Ettinger DS
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):48-54. PubMed ID: 7644928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel and carboplatin as neoadjuvant chemotherapy in operable (stage I and II) and locally advanced (stage IIIA-N2) non-small cell lung cancer.
    Splinter TA
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):59-61. PubMed ID: 9007124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.
    Williamson SK; Crowley JJ; Lara PN; McCoy J; Lau DH; Tucker RW; Mills GM; Gandara DR;
    J Clin Oncol; 2005 Dec; 23(36):9097-104. PubMed ID: 16361616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
    Patel JD; Bonomi P; Socinski MA; Govindan R; Hong S; Obasaju C; Pennella EJ; Girvan AC; Guba SC
    Clin Lung Cancer; 2009 Jul; 10(4):252-6. PubMed ID: 19632943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation dose in non-small cell lung cancer: too much of a good thing?
    Dilling TJ
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):979-82. PubMed ID: 25539360
    [No Abstract]   [Full Text] [Related]  

  • 20. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.